Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

被引：0

作者：

Alessandra Fabi

Luisa Carbognin

Andrea Botticelli

Ida Paris

Paola Fuso

Maria Cristina Savastano

Nicla La Verde

Carla Strina

Rebecca Pedersini

Stefania Guarino

Giuseppe Curigliano

Carmen Criscitiello

Mimma Raffaele

Alessandra Beano

Antonio Franco

Maria Rosaria Valerio

Francesco Verderame

Andrea Fontana

Eva Regina Haspinger

Alessia Caldara

Alba Di Leone

Giampaolo Tortora

Diana Giannarelli

Giovanni Scambia

机构：

[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology

[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health

[3] University of Rome,Medical Oncology Unit, La Sapienza

[4] Medical Oncology Unit,Department of Oncology and Hemato

[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology

[6] Medical Oncology Unit,Department of Medical Oncology1

[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences

[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery

[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility

[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined

[11] University of Milan,undefined

[12] Division of Early Drug Development,undefined

[13] European Institute of Oncology,undefined

[14] IRCCS,undefined

[15] Presidio Cassia Sant’andrea,undefined

[16] Dipartimento Oncologico,undefined

[17] Asl Roma1,undefined

[18] Città della Salute e della Scienza Hospital,undefined

[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined

[20] Medical Oncology,undefined

[21] Policlinico Universitario P. Giaccone,undefined

[22] Medical Oncology,undefined

[23] AO Riuniti Villa Sofia,undefined

[24] Cervello,undefined

[25] Medical Oncology Unit 2,undefined

[26] Azienda Ospedaliero-Universitaria Pisana,undefined

[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined

[28] Santa Chiara Hospital,undefined

[29] Medical Oncology,undefined

[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[31] Università Cattolica del Sacro Cuore,undefined

[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[33] Università Cattolica del Sacro Cuore,undefined

来源：

npj Breast Cancer | / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
Weiwei Huang
Chenxi Wang
Yangkun Shen
Qi Chen
Zhijian Huang
Jian Liu
Xiaoyan Lin
Lili Wang
Fan Wu
Xinhua Chen
Nani Li
Yi Hong
Mulan Chen
Jieyu Li
Chuanzhong Huang
BMC Cancer, 24
[42] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
Qiao Li
Jiaxuan Liu
Qingyuan Zhang
Quchang Ouyang
Yang Zhang
Qiang Liu
Tao Sun
Feng Ye
Baochun Zhang
Summer Xia
Bangyong Zhang
Binghe Xu
Nature Communications, 15
[43] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
Li, Qiao
Liu, Jiaxuan
Zhang, Qingyuan
Ouyang, Quchang
Zhang, Yang
Liu, Qiang
Sun, Tao
Ye, Feng
Zhang, Baochun
Xia, Summer
Zhang, Bangyong
Xu, Binghe
NATURE COMMUNICATIONS, 2024, 15 (01)
[44] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
Schmid, Peter
Cortes, Javier
Robson, Mark
Iwata, Hiroji
Hegg, Roberto
Verma, Sunil
Nechaeva, Marina
Xu, Binghe
Haddad, Vincent
Imedio, Esteban Rodrigo
Schiavon, Gaia
Foxley, Andrew
Park, Yeon Hee
CANCER RESEARCH, 2020, 80 (04)
[45] WHETHER CHIDAMIDE IMPROVES THE RESPONSE TO CISPLATIN IN FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Zhang, Jian
Hu, Xichun
Meng, Yanchun
Jin, Juan
Gong, Chengcheng
Miao, Haitao
Tao, Zhonghua
Li, Ting
Cao, Jun
Wang, Leiping
Wang, Biyun
Hu, Xichun
BREAST, 2021, 59 : S46 - S46
[46] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
Schmid, Peter
Cortes, Javier
Robson, Mark E.
Iwata, Hiroji
Hegg, Roberto
Nechaeva, Marina
Xu, Binghe
Verma, Sunil
Haddad, Vincent
Imedio, Esteban Rodrigo
Schiavon, Gaia
Foxley, Andrew
Park, Yeon Hee
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[47] Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
Montagna, Emilia
Bagnardi, Vincenzo
Cancello, Giuseppe
Sangalli, Claudia
Pagan, Eleonora
Iorfida, Monica
Mazza, Manuelita
Mazzarol, Giovanni
Dellapasqua, Silvia
Munzone, Elisabetta
Goldhirsch, Aaron
Colleoni, Marco
BREAST CARE, 2018, 13 (03) : 177 - 181
[48] Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
Adams, S.
Diamond, J.
Hamilton, E.
Pohlmann, P.
Tolaney, S.
Molinero, L.
Zou, W.
Liu, B.
Waterkamp, D.
Funke, R.
Powderly, J.
CANCER RESEARCH, 2016, 76
[49] Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Schmid, Peter
Abraham, Jacinta
Chan, Stephen
Wheatley, Duncan
Brunt, Adrian Murray
Nemsadze, Gia
Baird, Richard D.
Park, Yeon Hee
Hall, Peter S.
Perren, Timothy
Stein, Robert C.
Mangel, Laszlo
Ferrero, Jean-Marc
Phillips, Melissa
Conibear, John
Cortes, Javier
Foxley, Andrew
de Bruin, Elza C.
McEwen, Robert
Stetson, Daniel
Dougherty, Brian
Sarker, Shah-Jalal
Prendergast, Aaron
McLaughlin-Callan, Max
Burgess, Matthew
Lawrence, Cheryl
Cartwright, Hayley
Mousa, Kelly
Turner, Nicholas C.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
[50] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
Goto, Y.
Santorelli, M. L.
Taniguchi, K.
Kamitani, T.
Irisawa, M.
Kanda, K.
Abe, M.
Burke, T.
Nokihara, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009

← 1 2 3 4 5 →